Recurrent/Refractory Classical Hodgkin's Lymphoma
1 clinical trials · Condition
◉ Watch Recurrent/Refractory Classical Hodgkin's Lymphoma
| Record | Firm | Date |
|---|---|---|
| Phase 2 Multi-center Randomized Study to the Efficacy and Safety of AK105 Combined With Anrotinib Hydrochloride in Patients With Recurrent/Refractory Classical Hodgkin's Lymphoma (NCT05683704) | Tianjin Medical University Cancer Institute and Hospital | 2022-09-01 |
Track Recurrent/Refractory Classical Hodgkin's Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.